Drug Patents owned by Cardinal Health 414
1. Drug name - LYMPHOSEEK KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6409990 | CARDINAL HEALTH 414 | Macromolecular carrier for drug and diagnostic agent delivery |
May, 2025
(2 years from now) | |
| US9439985 | CARDINAL HEALTH 414 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran |
Sep, 2033
(10 years from now) | |
| CN102301429A | CARDINAL HEALTH 414 | Diethylenetriaminepentaacetic Acid (Dtpa)-Sephadex Gel For Radioactive Mark |
Aug, 2014
(8 years ago) | |
| EP1178838B1 | CARDINAL HEALTH 414 | Macromolecular Carrier Based On Dextran For Drug And Diagnostic Agent Delivery |
May, 2020
(2 years ago) | |
| EP1178838A2 | CARDINAL HEALTH 414 | Macromolecular Carrier Based On Dextran For Drug And Diagnostic Agent Delivery |
May, 2020
(2 years ago) | |
| EP2392012A1 | CARDINAL HEALTH 414 | Compositions For Radiolabeling Diethylenetriaminepentaacetic Acid (Dtpa)-Dextran |
Jan, 2030
(7 years from now) | |
| EP2392012B1 | CARDINAL HEALTH 414 | Compositions For Radiolabeling Diethylenetriaminepentaacetic Acid (Dtpa)-Dextran |
Jan, 2030
(7 years from now) | |
| EP2392012A4 | CARDINAL HEALTH 414 | Compositions For Radiolabeling Diethylenetriaminepentaacetic Acid (Dtpa)-Dextran |
Jan, 2030
(7 years from now) | |
Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| N/A | INJECTABLE;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.